Skip to content

Site Navigation

Exclusive Sponsored

PB Conference Learning Gallery

Search

Latest Stories

Start your day right!

Get the latest updates and insights delivered to your inbox

Enter your email

Exclusive Sponsored

PB Conference Learning Gallery

Advertise With Us Terms & Conditions Privacy Policy Cookie Policy Contact About Us Newsletter Subsciption Subscribe

Follow us

Home
biohaven pharmaceuticals

biohaven pharmaceuticals

Acute migraine? NICE recommends Pfizer's rimegepant as potential option

Pb Staff writer

Sep 14, 2023

Pfizer to pay Biohaven $11.6 bln to tap migraine market

Pb Staff writer

11 May 2022

Recent

load more

Advertise With Us Terms & Conditions Privacy Policy Cookie Policy Contact About Us Newsletter Subsciption Subscribe

© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc